Relationships among injury, fibrosis, and time in human kidney transplants

JCI Insight

Volumn 1, Issue 1, 2016, Pages

  Venner, Jeffery M ^a,b   Famulski, Konrad S ^a,c   Reeve, Jeff ^a,c   Chang, Jessica ^a   Halloran, Philip F ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Division of Nephrology and Immunology   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055597755     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.85323     Document Type: Article

References (87)

1. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014; 124(6):2333-2340.
2. Boor P, Floege J. Renal allograft fibrosis: biology and therapeutic targets. Am J Transplant. 2015; 15(4):863-886.
3. Rockey DC, Bell PD, Hill JA. Fibrosis - a common pathway to organ injury and failure. N Engl J Med. 2015; 372(1):1138-1149.
4. Risdon RA, Sloper JC, de Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet. 1968; 2(7564):363-366.
5. Haas M. Chronic allograft nephropathy or interstitial fibrosis and tubular atrophy: what is in a name? Curr Opin Nephrol Hypertens. 2014; 23(3):245-250.
6. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349(24):2326-2333.
7. Cosio FG, El TM, Cornell LD, Schinstock CA, Stegall MD. Changing kidney allograft histology early posttransplant: prognostic implications of 1-year protocol biopsies. Am J Transplant. 2016; 16(1):194-203.
8. Solez K, et al. Banff '05 Meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007; 7(3):518-526.
9. Racusen LC, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55(2):713-723.
10. Solez K, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008; 8(4):753-760.
11. Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK. Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. 2015; 26(8):1765-1776.
12. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984; 311(11):699-705.
13. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004; 78(4):557-565.
14. Famulski KS, Reeve J, de Freitas DG, Kreepala C, Chang J, Halloran PF. Kidney transplants with progressing chronic kidney diseases express high levels of acute kidney injury transcripts. Am J Transplant. 2013; 13(3):634-644.
15. El-Zoghby ZM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009; 9(3):527-535.
16. Einecke G, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009; 9(11):2520-2531.
17. Gaston RS, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010; 90(1):68-74.
18. Sellares J, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and non-adherence. Am J Transplant. 2012; 12(2):388-399.
19. Kotas ME, Medzhitov R. Homeostasis, inflammation, and disease susceptibility. Cell. 2015; 160(5):816-827.
20. Wickman L, et al. Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J Am Soc Nephrol. 2015; 24(12):2081-2095.
21. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol. 2010; 21(11):1987-1997.
22. Rodder S, Scherer A, Korner M, Marti HP. A subset of metzincins and related genes constitutes a marker of human solid organ fibrosis. Virchows Arch. 2011; 458(4):487-496.
23. Vitalone MJ, O'Connell PJ, Wavamunno M, Fung CL, Chapman JR, Nankivell BJ. Transcriptome changes of chronic tubulointerstitial damage in early kidney transplantation. Transplantation. 2010; 89(5):537-547.
24. Scian MJ, et al. MicroRNA profiles in allograft tissues and paired urines associate with chronic allograft dysfunction with IF/ TA. Am J Transplant. 2011; 11(10):2110-2122.
25. Mas VR, Dumur CI, Scian MJ, Gehrau RC, Maluf DG. MicroRNAs as biomarkers in solid organ transplantation. Am J Transplant. 2013; 13(1):11-19.
26. Mengel M, et al. Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am J Transplant. 2009; 9(1):169-178.
27. Einecke G, et al. Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Am J Transplant. 2008; 8(7):1434-1443.
28. Famulski KS, et al. Molecular phenotypes of acute kidney injury in human kidney transplants. J Am Soc Nephrol. 2012; 23(5):948-958.
29. Einecke G, et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest. 2010; 120(6):1862-1872.
30. Henderson NC, Forbes SJ. Hepatic fibrogenesis: from within and outwith. Toxicology. 2008; 254(3):130-135.
31. Reeve J, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant. 2013; 13(3):645-655.
32. Halloran PF, et al. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: the INTERCOM study. Am J Transplant. 2013; 13(9):2352-2363.
33. Halloran PF, et al. Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. J Am Soc Nephrol. 2015; 26(7):1711-1720.
34. Kreepala C, Famulski KS, Chang J, Halloran PF. Comparing molecular assessment of implantation biopsies with histologic and demographic risk assessment. Am J Transplant. 2013; 13(2):415-426.
35. Chung AC, Lan HY. MicroRNAs in renal fibrosis. Front Physiol. 2015; 6:50.
36. Venner JM, Famulski K, Badr D, Hidalgo LG, Chang J, Halloran PF. Molecular landscape of T cell-mediated rejection in human kidney transplants: Prominence of CTLA4 and PD ligands. Am J Transplant. 2014; 14(11):2565-2576.
37. Smith JC, Boone BE, Opalenik SR, Williams SM, Russell SB. Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J Invest Dermatol. 2008; 128(5):1298-1310.
38. Lawler PR, Lawler J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med. 2012; 2(5):a006627.
39. Puri V, Virbasius JV, Guilherme A, Czech MP. RNAi screens reveal novel metabolic regulators: RIP140, MAP4k4 and the lipid droplet associated fat specific protein (FSP) 27. Acta Physiol (Oxf). 2008; 192(1):103-115.
40. Mengel M, et al. The molecular phenotype of six-week protocol biopsies from human renal allografts: Reflections of prior injury but not future course. Am J Transplant. 2011; 11(4):708-718.
41. Stegall MD, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant. 2011; 11(4):698-707.
42. Famulski KS, et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant. 2007; 7(11):2483-2495.
43. Martini S, et al. Integrative biology identifies shared transcriptional networks in CKD. J Am Soc Nephrol. 2014; 25(11):2559-2572.
44. Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF. The molecular landscape of antibody-mediated kidney transplant rejection: Evidence for NK involvement through CD16a Fc receptors. Am J Transplant. 2015; 15(5):1336-1348.
45. Reeve J, et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant. 2009; 9(8):1802-1810.
46. Hancock WW, Thomson NM, Atkins RC. Composition of interstitial cellular infiltrate identified by monoclonal antibodies in renal biopsies of rejecting human renal allografts. Transplantation. 1983; 35(5):458-463.
47. Charney DA, Nadasdy T, Lo AW, Racusen LC. Plasma cell-rich acute renal allograft rejection. Transplantation. 1999; 68(6):791-797.
48. Gartner V, Eigentler TK, Viebahn R. Plasma cell-rich rejection processes in renal transplantation: morphology and prognostic relevance. Transplantation. 2006; 81(7):986-991.
49. Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol. 2007; 2(suppl 1):36-46.
50. Timoshanko JR, Kitching AR, Semple TJ, Tipping PG, Holdsworth SR. A pathogenetic role for mast cells in experimental crescentic glomerulonephritis. J Am Soc Nephrol. 2006; 17(1):150-159.
51. Veerappan A, et al. Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. Am J Physiol Renal Physiol. 2012; 302(1):F192-F204.
52. Papadimitriou JC, Drachenberg CB, Ramos E, Ugarte R, Haririan A. Mast cell quantitation in renal transplant biopsy speci mens as a potential marker for the cumulative burden of tissue injury. Transplant Proc. 2013; 45(4):1469-1471.
53. Wick G, et al. The immunology of fibrosis. Annu Rev Immunol. 2013; 31:107-135.
54. Stegall MD, Gaston RS, Cosio FG, Matas A. Through a glass darkly: seeking clarity in preventing late kidney transplant failure. J Am Soc Nephrol. 2015; 26(1):20-29.
55. Oberhuber R, Ge X, Tullius SG. Donor age-specific injury and immune responses. Am J Transplant. 2012; 12(1):38-42.
56. Maluf DG, et al. Evaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: input to chronic allograft dysfunction. Am J Transplant. 2014; 14(5):1152-1163.
57. Loupy A, et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol. 2014; 52(10):2267-2277.
58. Meier-Kriesche HU, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006; 6(5 pt 2):1111-1131.
59. Ekberg H, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-2575.
60. Ekberg H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009; 9(8):1876-1885.
61. Flechner SM, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant. 2004; 4(11):1776-1785.
62. Einecke G, Mengel M, Hidalgo LG, Allanach K, Famulski KS, Halloran PF. The early course of renal allograft rejection: Defining the time when rejection begins. Am J Transplant. 2009; 9(3):483-493.
63. Luyckx VA, Cairo LV, Compston CA, Phan WL, Mueller TF. Oncostatin M pathway plays a major role in the renal acute phase response. Am J Physiol Renal Physiol. 2009; 296(4):F875-F883.
64. Liu Q, et al. Suppressors of cytokine signaling inhibit tubular epithelial cell-myofibroblast transdifferentiation. Am J Nephrol. 2011; 34(2):142-151.
65. Trevillian P, Paul H, Millar E, Hibberd A, Agrez MV. A(v)beta(6) integrin expression in diseased and transplanted kidneys. Kidney Int. 2004; 66(4):1423-1433.
66. Zhong X, Chung ACK, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol. 2011; 22(9):1668-1681.
67. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 2010; 16(5):535-543.
68. Besnard AG, et al. CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model. J Leuk Biol. 2013; 94(6):1317-1323.
69. Kato H, et al. Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J Biol Chem. 2011; 286(29):26003-26015.
70. Kang HM, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015; 21(1):37-46.
71. Ahuja HS, Szanto A, Nagy L, Davies PJ. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J Biol Regul Homeost Agents. 2003; 17(1):29-45.
72. Wu J, et al. Peroxisome proliferator-activated receptors and renal diseases. Front Biosci (Landmark Ed). 2009; 14:995-1009.
73. Lu Y, et al. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Invest. 2014; 124(8):3501-3513.
74. Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol. 2000; 11(suppl 16):S140-S143.
75. Estrada K, et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA. 2014; 311(22):2305-2314.
76. Fernandez-Hernando C, Moore KJ. MicroRNA modulation of cholesterol homeostasis. Arterioscler Thromb Vasc Biol. 2011; 31(11):2378-2382.
77. Colgan SM, Hashimi AA, Austin RC. Endoplasmic reticulum stress and lipid dysregulation. Expert Rev Mol Med. 2011; 13:e4.
78. Hwang-Verslues WW, Sladek FM. HNF4α - role in drug metabolism and potential drug target? Curr Opin Pharmacol. 2010; 10(6):698-705.
79. Hodgin JB, et al. Glomerular aging and focal global glomerulosclerosis: a podometric perspective. J Am Soc Nephrol. 2015; 26(12):3162-3178.
80. Yang Y, et al. The two kidney to one kidney transition and transplant glomerulopathy: a podocyte perspective. J Am Soc Nephrol. 2015; 26(6):1450-1465.
81. Bricker NS, Morrin PAF, Kime SW. The pathologic physiology of chronic Bright's disease. An exposition of the "intact nephron hypothesis". Am J Med. 1960; 28:77-98.
82. Peti-Peterdi J, Harris RC. Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol. 2010; 21(7):1093-1096.
83. Bell PD, Lapointe JY, Peti-Peterdi J. Macula densa cell signaling. Annu Rev Physiol. 2003; 65:481-500.
84. Schnermann J. Homer W. Smith Award lecture. The juxtaglomerular apparatus: from anatomical peculiarity to physiological relevance. J Am Soc Nephrol. 2003; 14(6):1681-1694.
85. Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback: Adenosine, ATP, and Nitric Oxide. Annu Rev Physiol. 2003; 65:501-529.
86. Haas M, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014; 14(2):272-283.
87. Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57.